Search
Search Results
##search.searchResults.foundPlural##
-
PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations
3472PDF: 2364HTML: 1425 -
CAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CAR-T CELL and B-ALL
3885PDF: 3192HTML: 188 -
ROLE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
2786PDF: 1205HTML: 2679Figure 1: 155 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2002PDF: 1409HTML: 252 -
CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES CAR-T CELL FOR T-CELL MALIGNANCIES
2124PDF: 1961HTML: 158 -
DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA
8943PDF: 5995HTML: 87916Fig.1b: 171Fig.1c: 171Fig.2a: 164Fig.2b: 163Fig.4: 175Fig.2c: 170Fig.3: 169Tab.1: 215Tab.2: 194Tab.3: 180Tab.4: 207Fig1a: 165 -
MODERN IMMUNOTHERAPY OF ADULT B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA WITH MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS
2243PDF: 1310HTML: 17066Bassan Fig.1: 135Bassan Fig.2: 137Bassan Fig.4: 129Fig.3: 172 -
CENTRAL NERVOUS SYSTEM INVOLVEMENT IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: DIAGNOSTIC TOOLS, PROPHYLAXIS AND THERAPY
4002PDF: 1905HTML: 5202Table 1: 174 -
HHVs AND LYMPHOPROLIFERATIVE DISORDERS
1355PDF: 804HTML: 3109 -
NOVEL DRUGS IN FOLLICULAR LYMPHOMA
4266PDF: 1460HTML: 1535Untitled: 212 -
IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?
3328PDF: 1256HTML: 2201Fi.1 Gritti.Rambaldi: 192 -
Follicular Lymphoma: A Clinicopathological Analysis from a Tertiary care Institute in Southern India
3150PDF: 754HTML: 2925Figure 1a and 1b: 139Figure 2: 146Figure 3: 167Figure 4: 147Figure 5: 151Tables 1-5: 144 -
CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA CAR-T and CLL
3438PDF: 1486HTML: 67 -
LYMPHOPROLIFERATIVE SYNDROMES ASSOCIATED WITH HUMAN HERPESVIRUS-6A AND HUMAN HERPESVIRUS-6B
3697PDF: 1434HTML: 467Figures . Eliassian: 207 -
BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA BLINATUMOMAB and ALL
1565PDF: 1057HTML: 105 -
TDT Positive High-Grade Lymphoma with Myc, BCL2 And BCL6 Rearrangements: a Review of Diagnosis and Treatment TDT POSITIVE HIGH-GRADE LYMPHOMA WITH MYC, BCL2 AND BCL6 REARRANGEMENTS.
1642PDF: 731HTML: 472 -
CURRENT KNOWLEDGE ON HIV-ASSOCIATED PLASMABLASTIC LYMPHOMA
2542PDF: 1578HTML: 2344Table1: 181 -
CLINICAL ASPECTS AND THERAPY OF SPORADIC BURKITT LYMPHOMA
1250PDF: 597HTML: 3063 -
POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS: ROLE OF VIRAL INFECTION, GENETIC LESIONS AND ANTIGEN STIMULATION IN THE PATHOGENESIS OF THE DISEASE
1227PDF: 460HTML: 18551Figure 1: 154Figure 2: 138Figure 3: 156Figure 4: 189Figure 5: 160 -
CMV IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
4735PDF: 1730HTML: 2691Untitled: 197 -
ClinicaI Reversible Myelopathy in T-Cell Lymphoblastic Lymphoma Treated with Nelarabine and Radiotherapy: Report of a Case and Review of Literature of an Increasing Complication
2349PDF: 984HTML: 1637Fig 1: 171Tab I: 198Cover Letter: 190 -
CROCIN PROMOTES APOPTOSIS IN HUMAN EBV-TRANSFORMED B-LYMPHOCYTE VIA INTRINSIC PATHWAY CROCIN PROMOTES APOPTOSIS IN EBV-TRANSFORMED LCL
1211PDF: 456HTML: 130 -
IMMUNOTHERAPY FOR EPSTEIN-BARR VIRUS-RELATED LYMPHOMAS
1138PDF: 592HTML: 6788 -
AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA: NON-RANDOMIZED STUDY WITH A MAXIMUM FOLLOW-UP OF MORE THAN 22 YEARS
1507PDF: 888HTML: 1938Figure: 159Tables: 176ALL revision 1: 180response to reviewer: 166 -
DOWNREGULATION OF STEAROYL-COA DESATURASE 1 (SCD-1) PROMOTES RESISTANCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA Downregulation of Scd-1 in Chronic Myeloid Leukemia
1263PDF: 1156HTML: 432 -
REAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY Real-world Assessment of Myeloma Patients as Candidates for CAR-T Therapy
1515PDF: 579HTML: 175 -
SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival
1980PDF: 797HTML: 201 -
COMPARISON OF INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE AS GVHD AFTER TRANSPLANTATION FROM A 9/10 HLA-MATCHED UNRELATED DONOR WITH STANDARD GVHD PROPHYLAXIS AFTER TRANSPLANT FROM A FULL MATCHING DONOR Infection With PTCy Versus Standard GvHD Prophylaxis
1342PDF: 1277HTML: 84







